Table 1.

Results of hormone suppression treatments given before and during cytotoxic therapy on spermatogenic recovery in men.

				Recoveryb
Study	Disease	Cytotoxic therapy	Hormone treatment	Hormone-treated	Controls
Johnson et al., 1985	Hodgkin’s	MOPP 3–6 cycles	GnRH agonist	1 of 5	No controls
Waxman et al., 1987	Hodgkin’s	MVPP, ChlVPP	GnRH agonist + testosterone	0 of 20	0 of 10
Redman & Bajorunas, 1987	Hodgkin’s	MOPP ~4 cycles	Testosterone	≈70% of 23c	≈70% of 22c
Fossa et al., 1988	Testis Ca	PVB, ADR/CY, Radiation	Medroxy-progesterone	0 of 4 (2 of 12)d	2 of 3 (7 of 13)d
Kreuser et al., 1990	Testis Ca	PVB	GnRH agonist	6 of 6	8 of 8
Brennemann et al., 1994	Testis Ca (Seminoma)	Radiation	GnRH agonist + antiandrogen	12 of 12	8 of 8
Masala et al., 1997	Nephritis	Cyclophosphamide	Testosterone	5 of 5	1 of 5

^aChemotherapy regimens are as follows: MOPP, mechlorethamine, vincristine, procarbazine; and prednisone; MVPP, mechlorethamine, vinblastine, procarbazine, and prednisone; ChlVPP, chlorambucil, vinblastine, procarbazine, and prednisone; PVB: cisplatin, vinblastine, bleomycin; ADR/CY: Adriamycin, cyclophosphamide.

^bFraction of men recovering testicular function as assessed by restoration of sperm counts to normospermic levels unless otherwise noted.

^cActuarial recovery calculated by Kaplan-Meier analysis

^dRecovery assessed by restoration of FSH levels to within the normal control range.